Sanara MedTech Inc(SMTI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.71 | Insider Own | 46.9% | Shs Outstand | 9.2M | Perf Week | 0.11% |
| Market Cap | 0.30B | Forward P/E | 56.26 | EPS next Y | 207.89% | Insider Trans | - | Shs Float | 4.9M | Perf Month | -6.33% |
| Enterprise Value | 0.34B | PEG | - | EPS next Q | 0.06 | Inst Own | 19.79% | Short Float | 7.68% | Perf Quarter | -2.79% |
| Income | -0.03B | P/S | 2.75 | EPS this Y | 480% | Inst Trans | -8.52% | Short Ratio | 1.28 | Perf Half Y | 73.33% |
| Sales | 0.11B | P/B | 38.09 | EPS next 5Y | - | ROA | -0.34% | Short Interest | 0.37M | Perf YTD | 40.96% |
| Book/sh | 0.86 | P/C | 19.61 | EPS past 3/5Y | -63.11% -41.8% | ROE | -1.31% | 52W High | -7.33% ($35.52) | Perf Year | 11.8% |
| Cash/sh | 1.68 | P/FCF | 67.2 | Sales past 3/5Y | 31.03% 45.92% | ROIC | -57.08% | 52W Low | 105.12% ($16.05) | Perf 3Y | 22.45% |
| Dividend Est. | - | EV/EBITDA | 24.17 | EPS Y/Y TTM | -219.19% | Gross Margin | 90.77% | Volatility(W/M) | 1.84% 1.84% | Perf 5Y | -5.69% |
| Dividend TTM | - | EV/Sales | 3.06 | Sales Y/Y TTM | 12.93% | Oper. Margin | 10.38% | ATR (14) | 0.57 | Perf 10Y | 559.62% |
| Dividend Ex-Date | - | Quick Ratio | 2.3 | EPS Q/Q | 77.64% | Profit Margin | -29.15% | RSI (14) | 28.34 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.58 | Sales Q/Q | 8.93% | SMA20 | -3.2% ($34.01) | Beta | 1.22 | Target Price | $35 |
| Payout | - | Debt/Eq | 6.11 | Earnings | 2026/8/11 | SMA50 | -4.69% ($34.54) | Rel Volume | 0.12 | Prev Close | $32.88 |
| Employees | 108 | LT Debt/Eq | 6.06 | EPS/Sales Surpr. | -100% -2.81% | SMA200 | 29.41% ($25.44) | Avg Volume(3M) | 0.29M | Price | $32.92 |
| IPO | 1994/4/7 | Option/Short | No/Yes | Trades | 776 | Volume | 35,140 | Change | 0.11% |
🩹 This is a US medical device company that supplies collagen-based advanced wound care treatments and surgical adjuncts. It has a portfolio of high-margin surgical products, including CellerateRX Surgical and BIASURGE, and is targeting the surgical adjunct market through an extensive network of healthcare facilities and distribution partners.
Over the past 1 year, on the higher side
7% below its 1-year high.
Traded less than usual. That is 12% of its average volume.
SMTI keeps an operating profit but posts a net loss
Of every $100 in sales, $10.38 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +480.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $275. Peers typically go for $266. Compared with its own 3-year average, it is 78% cheaper now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -5.7%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 19.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #32 of 51 in the industry
Based on market cap of $302M.
FAQ
What kind of company is SMTI?
SMTI belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of SMTI?
The market cap of SMTI is approximately $302M, ranking 3,645 within its sector.
What is the 52-week high and low for SMTI?
SMTI has recorded a 52-week high of $35.52 and a low of $16.05.
